SCHEMBL6011075

SCHEMBL6011075

CC(C)(C)c1cccc(/C=C/C2CCN(C(=O)CN3CCOCC3)CC2)c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOB P27338 4/20 0.44
MAOA P21397 3/20 0.44
WNT3 P56703 1/20 0.42
SFRP1 Q8N474 1/20 0.42
ALOX15 P16050 1/20 0.41
TSHR P16473 1/20 0.41
HSD17B10 Q99714 1/20 0.41
NAMPT P43490 2/20 0.40
CNR2 P34972 1/20 0.40
ALDH1A1 P00352 2/20 0.39
RAB9A P51151 2/20 0.39
NPC1 O15118 1/20 0.39
HPGD P15428 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
KEAP1 Q14145 1/20 0.38
NFE2L2 Q16236 1/20 0.38
TRPV1 Q8NER1 1/20 0.38
MAPK1 P28482 1/20 0.38
KMT2A Q03164 1/20 0.37
TDP1 Q9NUW8 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10069891 0.88 RAB9A (0.53) MAOBWNT3SFRP1ALOX15TSHR
SCHEMBL6011043 0.88 RAB9A (0.53) MAOBWNT3SFRP1ALOX15TSHR
SCHEMBL10069075 0.87 MAPT (0.47) ALOX15TSHRHSD17B10NAMPTALDH1A1
SCHEMBL14261804 0.85 NPC1 (0.46) MAOBMAOAWNT3SFRP1ALOX15
SCHEMBL14261811 0.85 HTT (0.47) MAOBMAOAWNT3SFRP1ALOX15
SCHEMBL14261824 0.85 HTT (0.47) MAOBMAOAWNT3SFRP1ALOX15
SCHEMBL10069273 0.85 TSHR (0.44) MAOBMAOAWNT3SFRP1ALOX15
SCHEMBL6012016 0.85 KMT2A (0.46) MAOBMAOAALOX15TSHRHSD17B10
SCHEMBL6009399 0.85 MAOA (0.54) MAOBMAOAWNT3SFRP1ALOX15
SCHEMBL14261820 0.85 MAOA (0.54) MAOBMAOAWNT3SFRP1ALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1785415-B1 PIPERIDINE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF ASTELLAS PHARMA INC (JP) 2012-05-02 EP disclosed
US-20080070898-A1 Piperidine Derivative or Pharmaceutically Acceptable Salt Thereof ASTELLAS PHARMA INC. (JP) 2008-03-20 US disclosed
US-20080070898-A1 Piperidine Derivative or Pharmaceutically Acceptable Salt Thereof ASTELLAS PHARMA INC. (JP) 2008-03-20 US disclosed
EP-1785415-A1 PIPERIDINE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF Astellas Pharma Inc. (JP) 2007-05-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080070898-A1 Piperidine Derivative or Pharmaceutically Acceptable Salt Thereof TRPV1, TRPA1, CACNA1D MAOB 3198/4885MAOA 3281/4885WNT3 4096/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.